Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): A phase III, randomized, multicentre trial of the italian oncology group for clinical research (GOIRC)

Rodolfo Passalacqua, Caterina Caminiti, Sebastiano Buti, Camillo Porta, Roberta Camisa, Luca Braglia, Gianluca Tomasello, Augusto Vaglio, Roberto Labianca, Ermanno Rondini, Roberto Sabbatini, Giuseppe Nastasi, Fabrizio Artioli, Andrea Prati, Michele Potenzoni, Debora Pezzuolo, Elena Oliva, Federico Alberici, Carlo Buzio

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): A phase III, randomized, multicentre trial of the italian oncology group for clinical research (GOIRC)'. Together they form a unique fingerprint.

Medicine & Life Sciences